论文部分内容阅读
目的观察放射粒子125I植入联合化疗治疗非小细胞肺癌的临床疗效。方法选取非小细胞肺癌患者患者72例,随机分为观察组与对照组,每组36例。对照组予替吉奥联合奥沙利铂(SOX方案)化疗,观察组先予放射性125I粒子植入,植入粒子后5d进行化疗,化疗方案同对照组。观察2组治疗总有效率、不良反应发生率及远期疗效(2年生存率)。结果观察组总有效率为81.4%,高于对照组的51.2%(P<0.05);观察组不良反应发生率虽高于对照组,但2组比较差异无统计学意义;随访结果显示观察组2年生存率为66.7%,显著高于对照组的41.5%(P<0.05)。结论放射粒子125I植入联合化疗治疗非小细胞肺癌,可显著提高治疗总有效率,延长患者2年生存率,且不增加患者不良反应,值得临床推广应用。
Objective To observe the clinical effect of radioactive 125I implantation combined with chemotherapy on non-small cell lung cancer. Methods 72 patients with non-small cell lung cancer were selected and randomly divided into observation group and control group with 36 cases in each group. The control group was treated with GIO combined with oxaliplatin (SOX regimen) chemotherapy. The observation group received 125I radioactive seed implantation and chemotherapy was performed 5 days after the implantation of the particles. The chemotherapy regimen was the same as the control group. The total effective rate, incidence of adverse reactions and long-term effect (2-year survival rate) of two groups were observed. Results The total effective rate in the observation group was 81.4%, which was higher than that in the control group (51.2%, P <0.05). The incidence of adverse reactions in the observation group was higher than that in the control group, but there was no significant difference between the two groups. The 2-year survival rate was 66.7%, significantly higher than that of the control group (41.5%, P <0.05). Conclusion Radioactive 125I implantation combined with chemotherapy for non-small cell lung cancer can significantly improve the total effective rate, prolong the 2-year survival rate of patients, and does not increase the adverse reactions in patients. It is worthy of clinical application.